X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Spark secures exclusive worldwide rights to SpliceBio's proprietary Protein Splicing platform to develop, manufacture, and commercialize a gene therapy targeting an undisclosed inherited retinal disease.
Lead Product(s): Undisclosed
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Recipient: SpliceBio
Deal Size: $216.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 17, 2023
Details:
Neurochase is developing a proprietary drug delivery system and Spark will develop selected gene therapies for CNS disorders using the Neurochase technology, which aims to improve targeted delivery of AAV gene therapy to neural structures using the method of CED.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Neurochase
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 27, 2023
Details:
SPK-8011, a novel bio-engineered adeno-associated viral (AAV) vector utilizing the AAV-LK03 capsid, also referred to as Spark200, contains a codon-optimized human factor VIII gene under the control of a liver-specific promoter.
Lead Product(s): SPK-8011
Therapeutic Area: Genetic Disease Product Name: SPK-8011
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
SPK-8011, a novel bio-engineered adeno-associated viral (AAV) vector utilizing the AAV-LK03 capsid, contains a codon-optimized human factor VIII gene under the control of a liver-specific promoter.
Lead Product(s): SPK-8011
Therapeutic Area: Genetic Disease Product Name: SPK-8011
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2021
Details:
The agreement provides Spark with the exclusive, worldwide license to develop, manufacture and commercialize CG01. CombiGene will continue to execute certain aspects of the preclinical program in collaboration with Spark.
Lead Product(s): CG01
Therapeutic Area: Neurology Product Name: CG01
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CombiGene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 12, 2021
Details:
Under the terms of the agreement, Spark Therapeutics will receive access to NeuExcell's proprietary neuro-regenerative gene therapy platform and capabilities.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: NeuExcell therapeutics
Deal Size: $190.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 07, 2021
Details:
Investigational SPK-8011, a novel bio-engineered adeno-associated viral (AAV) vector utilizing the AAV-LK03 capsid, also referred to as Spark200, contains a codon-optimized human factor VIII gene under the control of a liver-specific promoter.
Lead Product(s): SPK-8011
Therapeutic Area: Genetic Disease Product Name: SPK-8011
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2021
Details:
All five patients in the 5x1011 vg/kg and 1×1012 vg/kg dose cohorts and seven participants in the 2×1012 vg/kg dose show an acceptable safety profile, stable & durable factor VIII expression and substantial improvement in annualized bleed rate after treatment with SPK-8011.
Lead Product(s): SPK-8011
Therapeutic Area: Genetic Disease Product Name: SPK-8011
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
